Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.9K Sell
43
-18
-30% -$1.2K ﹤0.01% 882
2026
Q1
$3.83K Buy
61
+26
+74% +$1.81K ﹤0.01% 697
2025
Q4
$2.32K Buy
35
+18
+106% +$1.16K ﹤0.01% 717
2025
Q3
$1.14K Sell
17
-15
-47% -$1.19K ﹤0.01% 846
2025
Q2
$2.79K Buy
+32
New +$2.51K ﹤0.01% 532

Other funds holding DXCM

Kilter Group's DXCM Position: Q2 2026 in Review

Kilter Group reduced its DexCom (DXCM) stake by 30% in Q2 2026, selling an estimated $1.2K and leaving 43 shares worth $2.9K. The position accounts for ﹤0.01% of the portfolio, ranked #882.

Kilter Group first reported a position in DXCM in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.83K in Q1 2026. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Kilter Group held 43 shares of DexCom worth $2.9K as of Q2 2026.
  • Kilter Group sold 18 DexCom shares in Q2 2026, an estimated $1.2K.
  • DexCom made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #882 holding.
  • Kilter Group first reported a position in DexCom in Q2 2025 and has held it in 5 quarters since.
  • Kilter Group's DexCom position peaked at $3.83K in Q1 2026.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.